Genmab A/S (GMAB) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Copenhagen, Denmark. 現CEOは Jan van de Winkel.
GMAB を有する IPO日 2009-06-01, 2,638 名の正社員, に上場 NASDAQ Global Select, 時価総額 $17.94B.
Genmab A/S is a Danish biopharmaceutical company founded in 1999 that develops antibody-based therapeutics for cancer and other serious diseases. The company's commercial portfolio includes DARZALEX (daratumumab) for multiple myeloma and other blood cancers, teprotumumab for thyroid eye disease, ofatumomab for chronic lymphocytic leukemia and multiple sclerosis, and amivantamab for gastric, esophageal, and lung cancers. Genmab maintains a robust pipeline of clinical and pre-clinical programs, including tisotumab vedotin for solid tumors, epcoritamab for lymphomas, and multiple early-stage candidates in Phase 2 development across oncology and other therapeutic areas. The company partners with leading pharmaceutical and biotech firms including Seagen, AbbVie, Janssen, BioNTech, and Novo Nordisk to advance its research and development efforts globally.
